{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000040","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.502826+00:00","generated_at":"2026-06-10T10:41:58.668533+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aurinia appoints founder Dr. Foster to board; enters cooperation agreement with MKT Capital","bullets":["Dr. Robert T. Foster appointed to Board effective Sept 21, 2023; term expires at 2024 Annual Meeting.","MKT Capital agrees to standstill until Oct 31, 2024 (with conditions) and 7% ownership cap.","Dr. Foster receives standard non-employee director compensation: $45K annual cash, $200K annual equity, $340K new director grant.","Dr. Foster retains 2% royalty on voclosporin licensee sales and 0.3% of direct net sales ($307,254 in FY2022).","Press release notes Dr. Foster discovered voclosporin; strategic review remains ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000040","json":"https://secwatch.observer/filing/0001600620-23-000040.json","markdown":"https://secwatch.observer/filing/0001600620-23-000040.md","text":"https://secwatch.observer/filing/0001600620-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/0001600620-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/auph-20230921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:41:58.668533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78ef12643a","claim":"Dr. Robert T. Foster was appointed as Board member at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"In connection with the Cooperation Agreement, Dr. Foster was appointed to the Board, effective September 21, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000040/0001600620-23-000040-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Board member"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}